Key statistics
On Friday, Vaxcyte Inc (5VA:STU) closed at 47.40, 91.13% above the 52 week low of 24.80 set on Apr 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 44.20 |
|---|---|
| High | 47.40 |
| Low | 43.00 |
| Bid | 47.20 |
| Offer | 47.80 |
| Previous close | 45.40 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 141.03m |
| Free float | 140.35m |
| P/E (TTM) | -- |
| Market cap | 7.60bn USD |
| EPS (TTM) | -4.84 USD |
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Announcements
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte Announces Pricing of $550 Million Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
- Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
- Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
- Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
- Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
- Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
More ▼
